Document Detail

In Vitro Metabolism of 20(R)-25-Methoxyl-Dammarane-3, 12, 20-Triol from Panax notoginseng in Human, Monkey, Dog, Rat, and Mouse Liver Microsomes.
Jump to Full Text
MedLine Citation:
PMID:  24736630     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The present study characterized in vitro metabolites of 20(R)-25-methoxyl-dammarane-3β, 12β, 20-triol (20(R)-25-OCH3-PPD) in mouse, rat, dog, monkey and human liver microsomes. 20(R)-25-OCH3-PPD was incubated with liver microsomes in the presence of NADPH. The reaction mixtures and the metabolites were identified on the basis of their mass profiles using LC-Q/TOF and were quantified using triple quadrupole instrument by multiple reaction monitoring. A total of 7 metabolites (M1-M7) of the phase I metabolites were detected in all species. 25(R)-OCH3-PPD was metabolized by hydroxylation, dehydrogenation, and O-demethylation. Enzyme kinetic of 20(R)-25-OCH3-PPD metabolism was evaluated in rat and human hepatic microsomes. Incubations studies with selective chemical inhibitors demonstrated that the metabolism of 20(R)-25-OCH3-PPD was primarily mediated by CYP3A4. We conclude that 20(R)-25-OCH3-PPD was metabolized extensively in mammalian species of mouse, rat, dog, monkey, and human. CYP3A4-catalyzed oxygenation metabolism played an important role in the disposition of 25(R)-OCH3-PPD, especially at the C-20 hydroxyl group.
Authors:
Xiangrong Zhang; Ji Zhang; Wei Li; Li Liu; Baoshan Sun; Zhenghong Guo; Caihong Shi; Yuqing Zhao
Publication Detail:
Type:  Journal Article     Date:  2014-04-15
Journal Detail:
Title:  PloS one     Volume:  9     ISSN:  1932-6203     ISO Abbreviation:  PLoS ONE     Publication Date:  2014  
Date Detail:
Created Date:  2014-04-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101285081     Medline TA:  PLoS One     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e94962     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
ISSN: 1932-6203
Publisher: Public Library of Science, San Francisco, USA
Article Information
Download PDF
Copyright: 2014 Zhang et al
License:
Received Day: 12 Month: 12 Year: 2013
Accepted Day: 20 Month: 3 Year: 2014
collection publication date: Year: 2014
Electronic publication date: Day: 15 Month: 4 Year: 2014
Volume: 9 Issue: 4
E-location ID: e94962
PubMed Id: 24736630
ID: 3988085
Publisher Id: PONE-D-13-52495
DOI: 10.1371/journal.pone.0094962

In Vitro Metabolism of 20(R)-25-Methoxyl-Dammarane-3, 12, 20-Triol from Panax notoginseng in Human, Monkey, Dog, Rat, and Mouse Liver Microsomes Alternate Title:Metabolism of Panax notoginseng
Xiangrong Zhang1
Ji Zhang2
Wei Li1
Li Liu2
Baoshan Sun1
Zhenghong Guo1
Caihong Shi1
Yuqing Zhao13*
Junxuan Luedit1 Role: Editor
1School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, Liaoning, China
2Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, Jiangsu, China
3Key Laboratory of Research and Design of “Drug Targets Based on the Ministry of Education”, Shenyang Pharmaceutical University, Shenyang, Liaoning, China
Texas Tech Univ School of Pharmacy, United States of America
Correspondence: * E-mail: yuqingzhao@syphu.edu.cn
[conflict] Competing Interests: The authors have declared that no competing interests exist.
Contributed by footnote: Conceived and designed the experiments: XZ WL LL YZ. Performed the experiments: XZ JZ WL BS CS. Analyzed the data: XZ LL ZG YZ. Contributed reagents/materials/analysis tools: XZ WL BS ZG CS. Wrote the paper: XZ WL YZ.

Introduction

Panax ginseng, a traditional herbal medicine used in the Eastern Asia for more than 2000 years, is presently being used worldwide as one of the most common complementary alternative medicines [1]. Ginseng, the root of Panax ginseng, has various health benefits, ranging from overcoming fatigue to treating severe cardiac and cancer problems [2][5]. 25-methoxydammarane-3, 12, 20-triol (25-OCH3-PPD) was a novel dammarane-type triterpene sapogenin that was first reported by Zhao [6], [7], from the leaves of P.notoginseng. 25-OCH3-PPD exerts the strongest activity among any of the known ginsenosides tested for cytotoxic effects [8]. It is an effective inhibitor of cell growth and proliferation and inducer of apoptosis and cell cycle arrest. 25-OCH3-PPD had significant, dose-dependent effects on apoptosis, proliferation, and cell cycle progression. Preclinical data indicate that 25-OCH3-PPD is a potential therapeutic agent against prostate cancer [9] and human breast cancer through down-regulating MDM2 [10]. 25(R)-OCH3-PPD (Figure 1) showed anti-lung cancer activity by activation of p38 MAPK pathway and generation of reactive oxygen species [11].

20(S) and 20(R) forms of 25-OCH3-PPD are stereoisomers of each other that depend on the orientation of the C-20 hydroxyl. During the preclinical evaluation, we found that 25(S)-OCH3-PPD could be absorbed with an absolute bioavailability of 19.7% ±7.6% (10 mg/kg) in rats [12]. 25-OCH3-PPD was converted to 25-OH-PPD in rats after oral gavage or iv injection. 25(S)-OCH3-PPD was metabolized to form active 25-OH-PPD after oral and intravenous administration. Plasma level of 25-OH-PPD was greater than that of 25-OCH3-PPD. However, 25-OH-PPD was less active than parent compounds in vitro[6]. The pharmacokinetic profiles of 25(R)-OCH3-PPD and 25(S)-OCH3-PPD were different. 25(R)-OCH3-PPD was absorbed less than that of 25(S)-OCH3-PPD in rats [13].

It is important to examine whether or not 25(R)-OCH3-PPD was metabolized by drug-metabolizing enzyme(s) in liver microsomes and then attempted to elucidate human P450 isoform(s) responsible for the biotransformation of 25(R)-OCH3-PPD. The study of hepatic microsomal-mediated metabolism will be of great significance for understanding of their systematic disposition and of 25(R)-OCH3-PPD-drug interaction and the mechanisms involved.

The objectives of the present study were as follows: 1) to characterize the structures of oxidative metabolites of 25(R)-OCH3-PPD, 2) to examine the difference of metabolism of 25(R)-OCH3-PPD by rodent (mice and rats) and nonrodent (dogs and monkeys) animal species hepatic microsomes and 3) to identify the cytochrome P450 (P450) and non-P450 enzymes responsible for 25(R)-OCH3-PPD biotransformation.


Materials and Methods
Reagents

25(R)-OCH3-PPD and 25(R)-OH-PPD (99.0% pure) were supplied by Shenyang Pharmaceutical University (Liaoning, P. R. China). Pooled human liver microsomes (HLM), male cynomolgus monkey liver microsomes (CyLM), male beagles [dog liver microsomes (DLM)], male Sprague-Dawley rats [rat liver microsomes (RLM)], and male CD-1 mice [mouse liver microsomes (MLM)], as well as recombinant P450 enzymes CYP3A4 were purchased from Research Institute for Liver Diseases (Shanghai) Co., Ltd. (Shanghai, China). NADPH, NAD+, glucose-6-phosphate (G-6-P) and glucose-6-phosphate dehydrogenase (G-6-PDH) were purchased from Sigma-Aldrich (St.Louis, MO). All solvents used for high-performance liquid chromatography (HPLC) were of HPLC grade (Merck, Darmstadt, Germany). Chemical inhibitors, ketoconazole (Ket), α-naphthoflavone (Naph), sulfaphenazole (Sul), quercetin (Que), quinidine (Qui),diethyl dithiocarbamate (DDC) and ticlopidine (TP) (purity >99%) were purchased from Sigma-Aldrich (Shanghai, China). Purified water was generated with a Milli-Q Gradient system (Millipore Corporation, Molsheim, France).

Chromatography of 25(R)-OCH3-PPD and Metabolites

The Agilent 1200 HPLC system was equipped with a reversed-phase column (Atlantis T3C18, 2.1×150 mm i.d., 5 µm; Waters CA) protected by a 4.0×3.0 mm i.d. Security Guard (5 µm) C18 guard column (Phenomenex, Torrance, CA). Mobile phases A and B consisted of 0.1% (volume fraction) formic acid in water and methanol, respectively. Gradient elution at a flow rate of 0.2 ml/min was with the following program: initial 70% B for 3 min, increased to 95% in 14 min, maintaining this condition for 8 min, ramping back down to 70% B in 1 min and holding at this condition for a further 4 min, to give a total runtime of 30 min.

Mass Spectrometry

The initial screening of the compounds’ metabolites and accurate mass measurements was carried out using Agilent liquid chromatography quadrupole – time –of–flight mass spectrometer (LC-Q/TOF) 6520 mass spectrometer. A generic positive electrospray ionization method was used for all substrates and metabolites. The capillary voltage was 3500 V, cone voltage 20 V, and desolvation and source temperatures 260 and 150°C, respectively. Nitrogen was used as the desolvation and cone gas with flow rates of 900 and 300 L/h. All data acquired were processed using Mass Hunter Qualitative Analysis Software (B.04.00, Agilent).

The quantification (multiple reaction monitoring, MRM) and fragmentation measurements were performed with Shimadzu LC-MS/MS-8030 triple quadrupole instrument following positive mode electrospray ionization (ESI). The capillary voltage was 4500 V, and desolvation and source temperatures 250 and 150°C, respectively. The collision gas was argon with a CID gas cell pressure of 2.0×103 mbar. Nitrogen was used as the drying and nebulizing gas with flow rates of 90 and 15 L/h. The data generated was processed using Shimadzu LabSolutions version 5.

Metabolism by Human, Monkey, Dog, Rat, and Mouse Liver Microsomes

25(R)-OCH3-PPD were incubated in hepatic microsomes to examine the potential P450-mediated metabolism. Stock solutions of 2 mM 25(R)-OCH3-PPD was prepared in methanol. The final methanol concentration in the incubation was 2.5% (v/v). The liver microsomes were carefully thawed on ice before the experiment.

For NADPH dependent oxidative metabolism study, the reaction media contained 1 mg/ml of microsomal proteins, 10 mM G-6-P, 10 mM MgCl2, 1 U/ml G-6-PDH, 50 µM concentration of 25(R)-OCH3-PPD in potassium phosphate buffer (pH 7.4; 0.1 M) in a total volume of 200 µl. Negative control incubations containing no NADPH-regenerating system were conducted. All incubations were performed at 37°C in a shaking water bath for 60 min.

After 5 min preincubation at 37°C, the incubation reactions were initiated with the addition of microsome proteins. After undergoing incubation for 60 min, the reactions were terminated with an equal volume of ice-cold acetonitrile and 10 µl diazepam (5 µg/ml, internal standard) was added. This sample was vortex-mixed and centrifuged at 14,000 g for 5 min. The supernatant was transferred into a glass tube, evaporated to dryness under a stream of nitrogen at 40°C. The residue was reconstituted in 100 µl of methanol with 0.1% formic acid, centrifuged 10 min at 18000 rpm and then an aliquot 5 µL of the supernatant was directly injected onto the HPLC-MS system for quanlitative or quantitative analysis.

Chemical Inhibition Study in Human Hepatic Microsomes

The chemical inhibition study was performed by adding each of the specific inhibitors of P450 enzymes into the incubation of 25(R)-OCH3-PPD (3 or 10 µM) in 0.25 mg/ml HLM incubation systems containing an NADPH-regenerations system as described above. The chemical inhibitors and concentration were selected on the basis of previous reports and are as follows: α-naphthoflavone (10.0 µM) for CYP1A2, quercetin (10 µM) for CYP2C8, sulfaphenazole (10.0 µM) for CYP2C9, ticlopidine (5 µM) for CYP2C19, quinidine (10.0 µM) CYP2D6, diethyl dithiocarbamate (20 µM) for CYP2E1, and ketoconazole (0.1, 0.25, 0.5, 1 and 5 µM) for CYP3A.

The inhibitors were dissolved in dimethyl sulfoxide, and the final concentration of dimethyl sulfoxide in the incubation was 1% (v/v). The final incubation volume was 200 µl. Microsomes were preincubated for 5 min with a NADPH-regenerating system at 37°C, the reactions were initiated with the addition of 25(R)-OCH3-PPD and inhibitor. The reactions were terminated with an equal volume of ice-cold acetonitrile after 30 min of incubation. Parallel incubations without chemical inhibitors served as control. Samples were prepared as mentioned above to measure the concentration of parent and the metabolites by HPLC-MS/MS analysis.

Recombinant Enzyme Incubations

25(R)-OCH3-PPD (3, 10 µM) was incubated in duplicate at 37°C for 30 min with a panel of recombinant human P450 enzymes CYP3A4, at 4 pmol/ml. NADPH-regenerations system was the same as part of metabolism by human, monkey, dog, rat, and mouse liver microsomes. Samples were prepared as previously described and an aliquot 5 µl was subjected to HPLC-MS/MS analysis to measure the metabolites formed. Parallel incubations without NADPH-regenerations system served as control.

Enzymatic Kinetics of 25(R)-OCH3-PPD Metabolism by HLM

25(R)-OCH3-PPD was incubated with 0.25 mg/ml HLM at eleven different concentrations (1, 2, 3, 4, 5, 7.5, 10, 15, 20, 30, 50 µM). Reactions were kept at 37°C for 30 min, and then terminated with 200 µl of ice-cold acetonitrile containing IS. HPLC-MS/MS analyses of samples were the same as mentioned above. The apparent Km, Vmax values were estimated by nonlinear regression from the Lineweaver-Burk plots based on typical Michaelis-Menten equation. The intrinsic clearance was calculated as Vmax/Km. Data are expressed as the mean ± S.D. of triplicate experiments.

Statistical Analysis

All of the data reported represent the mean ± standard deviation. All experiments were conducted at least twice. The t-test was used for the statistical data analysis and the level of significant was set at p-value of 0.05.


Results
Mass Spectral Properties of 25(R)-OCH3-PPD and Metabolites

A comprehensive understanding of the fragmentation behavior of the parent compound to be tested can be very helpful in metabolite identification using LC-Q/TOF. 25(R)-OCH3-PPD incubated with hepatic microsomes resulted in seven metabolites was detected from the extracted mass chromatograms, and 25(R)-OH-PPD was identified with the help of standards. Under the experimental conditions, the 25(R)-OCH3-PPD molecule (m/z 493) was detected under positive scan mode (Figure 2A) and m/z 515 was [M+Na]+. In the MS2 spectrum (Figure 2B), 25(R)-OCH3-PPD displayed diagnostic fragment ions were 475, 457, 443, 425, and 407. Figure 3 showed the spectrum of 25(R)-OH-PPD (m/z 479) was detected under positive scan mode (Figure 3A) and m/z 501 was [M+Na]+. In the MS2 spectrum fragment ions were 461, 443, 425, 407 (Figure 3B).

LC/MS/MS Analysis by Triple Quadrupole Mass Spectrometry

When 25(R)-OCH3-PPD was incubated without NADPH or microsomes, no metabolites were generated; indicating that there were no chemical reactions under the incubation conditions. Figure 4 showed extracted ion chromatograms of the parent drug and 7 metabolites after incubation in the human liver microsome. Table 1 showed the retention time, MS/MS fragment ions of 25 (R)-OCH3-PPD and its metabolites under the present conditions. The phase I metabolite profiles of 25(R)-OCH3-PPD were found in all species. Proposed in vitro metabolic pathways of 25(R)-OCH3-PPD in human and rat microsomes were shown in Figure 5.

The quantification for 25(R)-OCH3-PPD was performed with the transitions of m/z 493.5→425.3 and m/z 479.5→425.3 for 20(R)-25-OH-PPD. Diazepam with the transition of m/z 285.0→154.0 was employed as an internal standard. The assessment of bioanalytical method validation has been described elsewhere [13], [14]. The other metabolites were only semi-quantitated using the ratios of their peak areas relative to that of the internal standard. According to the character of metabolite by MRM in the positive mode was performed using the MS/MS fragment ions, m/z 493.3→439.3 (M2), 495.3→441.3 (M3), 507.3→439.3 (M4), 509.3→455.3 (M5), 509.3→459.3 (M6), 523.3→455.3 (M7).  Mean metabolite amounts found in samples incubated for 60 min are shown in Figure 6. It could be observed that the amount of overall metabolism varied among species.

Structure Elucidation of 25(R)-OCH3-PPD Metabolites in Human, Monkey, Dog, Rat, and Mouse Liver Microsomes

These metabolites were numbered according to the structures were elucidated through their mass spectral fragments and relationship with each other.

25(R)-OCH3-PPD (M0) had retention time (TR) of 20.7 min and showed protonated molecular ion [M+H]+ at m/z 493. M0 showed identical fragment ions compared with the parent compound. The chromatography and mass character is the same with 25(R)-OCH3-PPD. The MS2 spectrum of 25(R)-OCH3-PPD showed major product ions at m/z 475, 457, 443, 425 and 407. The product ion at m/z 443 indicates the loss of methyl group (14 Da).

M1 was observed at 19.1 min with [M+H]+ ion at m/z 479. The MS2 spectrum of M1 showed major fragment m/z 461, 443, 425 and 407. The m/z value was 14 Da less than that of 25(R)-OCH3-PPD, indicating a 25-demethylated metabolite, as was reported in a previous study [14]. Furthermore, comparison with the authentic 25(R)-OH-PPD standard showed identical retention time and MS/MS fragmentation pattern. The lost of 14 Da was used as a key ion for the structural elucidation of 25(R)-OCH3-PPD metabolites.

M2 was detected at 11.0 min with [M+H]+ ion at m/z 493. The product ion scan showed at m/z 475, 457, 439, 421 and 403. The 14 Da could not found at MS-MS and indicated lost of methyl group. The m/z value of M2 was 2 Da less than that of M3, to deduce the dehydrogenation of M3.

M3 had a retention time of 10.5 min with [M+H]+ ion at m/z 495. The MS2 spectrum of the M3 [M+H]+ ions showed major fragment m/z 477, 459, 441, 423 and 405. The product ion m/z value was 16 Da higher than that for M1, suggesting hydroxylated product of M1. However, the exact position of M1 hydroxylation could not be determined based on the results of this data. The fragment ion of m/z 459 indicated that +16 modification occurred in the dammarane aglycone moiety [16].

M4 was observed at 15.5 min with [M+H]+ ions at m/z 507. The MS2 spectrum of the M4 [M+H]+ ions showed major fragment ions m/z 489, 471, 457, 439, 421 and 403. The fragment is similar with M6 and the group of methyl was lost. The m/z value of M4 was 2 Da less than that of M6, indicating the dehydrogenation of M6. However, the dehydrogenation position cannot be determined by the current data.

M5, 6 were eluted at 10.1 min and 14.8 min with [M+H]+ ions at m/z 509. The product ions of M5 at m/z 491, 473, 455 and 437 correspond to 16-Da higher forms of the product ions of M2 (475, 457, 439, 421), indicating hydroxylated M2 metabolite. The polarity character of this structure was in accordance with its retention time. The product ions of M6 showed major fragment m/z 491, 473, 459, 441 and 423. The m/z value was 16 Da higher than that of parent compound, indicating hydroxylated metabollite of 25(R)-OCH3-PPD.

M7 was observed at 14.1 min with [M+H]+ ion at m/z 523. The m/z value [M+H]+ ions was 16 Da heavier than that for the protonated M4, indicating the introduction of 1 oxygen molecule. The MS2 spectra of M7 showed major fragment ions at m/z 505, 487, 473, 455 and 437. The product ions correspond to 16-Da higher of the product ions of M4 (m/z 489,471,457,439,421), indicating hydroxylation of M4.

Chemical Inhibition Study in Human Hepatic Microsomes

Among various specific chemical inhibitors were used, only ketoconazole showed a significant inhibitory effect on the oxidative metabolism of 25(R)-OCH3-PPD (Figure 7). All other P450 isoform-specific inhibitors resulted in a negligible effect on the oxygenation metabolism of 25(R)-OCH3-PPD. P450 3As were probably the major enzymes responsible for the oxidative metabolism of 25(R)-OCH3-PPD. As expected, the oxidative metabolites of 25(R)-OCH3-PPD were detected in the incubations only with CYP3A4. The phase I metabolite profile of 25(R)-OCH3-PPD in CYP3A4 was shown in Figure 8.

Enzymatic Kinetics of 25(R)-OCH3-PPD Metabolism by HLM

Table 2 showed summary of Km and Vmax values for metabolite formation in human liver microsome. Results from the inhibition of an enzymatic process can have serious implications for clinical drug therapy. Preliminary experiments were performed to ensure that the depletion of parent compound was in the linear range of both reaction time and protein concentration of microsomes. The apparent Km for M2, M5, M7 was<5 µM under our conditions; but the value Km for M1, M3, M4, M6 was 19–30 µM, and the Vmax value ranged from 11.3 (M2) to 165 (M4) pmol/min/mg protein.


Discussion

The possible cancer preventive activity of Panax notoginseng is receiving more and more attention. Information on the metabolism of Panax notoginseng components is important for understanding the biological effects of Panax notoginseng. Some reports concerned the structure-activity relationship and substrate-dependent phenomena in effects of Ginsenosides on P450 Enzymes [15], [16]. Previously, we reported the pharmacokinetics of 25(R)-OCH3-PPD in rat. Thus far, the differences in the metabolic pathways and behaviors of 25(R)-OCH3-PPD between human and common experimental animals have not been revealed. Hence, in this study a comparison of metabolic profiles, enzymes involved, and catalytic efficiency for 25(R)-OCH3-PPD metabolism in liver microsomes from different species was performed.

The products of 25(R)-OCH3-PPD biotransformation with liver microsomes in vitro were first analyzed using LC–TOF–MS. We speculated structures of the metabolites in positive-ion mode on the fragment rules. Then, the parent compound and M1–M7 were quantified by LC/MS/MS performed on Shimadzu LC-MS/MS-8030 following positive mode electrospray ionization.

A total of 7 metabolites were identified based on the retention times, molecular weights, parent ions and fragment ions which are presented in Table 1. The proposed metabolic pathways of 25(R)-OCH3-PPD in liver microsome were shown in Figure 5. These metabolites may be classified into three types: demethylation (M1, M2, M3 and M5), dehydrogenation (M2 on base of M3), (M4 on base of M6) and hydroxylation (M6 on base of M0, M3 on base of M1, M5 on base of M2, M7 on base of M4). Future works need to confirm whether demethylation was formed from M6 to M3, M4→M2 and M7→M5. The methyl group was easily removed by phase I enzymes and hydroxylation derivatives were the main metabolites.

We were only able to investigate the metabolites M2–M7 by semi-quantitated method due to the lack of authentic standards. The intrinsic clearance (Vmax/Km) ranked as follows: M3< M1< M6< M5< M4< M2< M7 (Table 2). It was necessary to address the observed discrepancies of catalytic efficiencies among the animal liver microsomes. The study revealed a comparative metabolism of 25(R)-OCH3-PPD in liver microsomes from mouse, rat, dog, monkey, and human. The metabolites were similar across all animal species, with a few distinct differences in amount (Figure 6).

Metabolite M1 was the dominant metabolite from the rodent species after incubation of 25(R)-OCH3-PPD with microsomes, was found in an intermediate relative amount in dog, and was a minor metabolite in monkey and human microsomes. In addition M3 and M5 were the major product of 25(R)-OCH3-PPD metabolism in HLM, but a very minor product of incubation from microsomes of MLM and in dog. However, the more metabolites M4 and M7 were found in all species. In particular, M5 was the major metabolite in CyLM and HLM under our experimental parameters, while this compound was minor in all other species, with the smallest amount produced from DLM incubation.

For further exploration of the similarity of the enzymes responsible for the metabolism of 25(R)-OCH3-PPD from various species, chemical inhibition studies with selective general inhibitors were administrated. Ketoconazole inhibited the formation of M2, M3, M4, M5, M7 and showed concentration dependent (Figure 7). Ketoconazole inhibited the formation of M5 completely at concentration of 0.1 µM. Ketoconazole (0.1–1 µM) activated formation of M1 and M6, but at 5 µM inhibited the formation of M1 and M6. The reason is that M1 and M6 were not sensitive to ketoconazole.

Both chemical inhibition studies and recombinant enzyme screen results showed that CYP3A4 was the major P450 isoform in formation of all oxidative metabolites of 25(R)-OCH3-PPD and M7 was with the largest amount among the metabolites. Previous work by Li et al [16] demonstrated that CYP3A4 contributed to the formation of all oxidative metabolites of Rh2. Rh2 is also a dammarane-type triterpenoid saponin formed by a glucose sugar moiety glycosidically bonded to the hydroxy group at the C-3 position of 20(S)-protopanaxadiol (PPD). The inhibition of the CYP3A4 catalytic activity by 25(R)-OCH3-PPD was NADPH and concentration-dependent, which supplies a possible explanation for the low absorption of 25(R)-OCH3-PPD in rats in our previous research.


Conclusions

This report gave an in-depth exploration of 20(R)-25-OCH3-PPD metabolisms in liver microsomes from mouse, rat, dog, monkey, and human. A qualitative profiling by LC/TOF-MS led to the qualitative detection of seven metabolites, including hydroxylation, dehydrogenation and O-demethylation. LC/MS/MS analysis was used to quantify parent and metabolites in different microsomes with NADPH-dependent. CYP3A4 was the predominant enzyme involved in the oxidative metabolism. These data are fundamental toward future work in 20(R)-25-OCH3-PPD chemoprevention.


References
1. Helms S, (Year: 2004) Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev9: 259–27415387718
2. Attele AS,, Wu JA,, Yuan CS, (Year: 1999) Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol58: 1685–169310571242
3. Dang H,, Chen Y,, Liu X,, Wang Q,, Wang L,, et al. (Year: 2009) Antidepressant effects of ginseng total saponins in the forced swimming test and chronic mild stress models of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry33: 1417–142419632285
4. Yoo JH,, Kwon HC,, Kim YJ,, Park JH,, Yang HO, (Year: 2010) KG-135, enriched with selected ginsenosides, inhibits the proliferation of human prostate cancer cells in culture and inhibits xenograft growth in athymic mice. Cancer Letters289: 99–11019765891
5. Wang W,, Rayburn ER,, Hang J,, Zhao Y,, Wang H,, et al. (Year: 2009) Anti-lung cancer effects of novel ginsenoside 25-OCH3-PPD. Lung Cancer65: 306–31119131140
6. Wang W,, Rayburn ER,, Zhao Y,, Wang H,, Zhang R, (Year: 2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer lett278: 241–24819203832
7. Zhao JM,, Li N,, Zhang H,, Wu CF,, Piao HR,, et al. (Year: 2011) Novel dammarane-type sapogenins from Panax ginseng berry and their biological activities. Bioorg Med Chem Lett21: 1027–103121216145
8. Zhao Y,, Wang W,, Han L,, Rayburn ER,, Hill DL,, et al. (Year: 2007) Isolation, structural determination, and evaluation of the biological activity of 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol [20(S)-25-OCH3-PPD], a novel natural product from Panax notoginseng. Med Chem3: 51–6017266624
9. Wang W,, Wang H,, Rayburn ER,, Zhao Y,, Hill DL,, et al. (Year: 2008) 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action. Br J Cancer98: 792–80218253123
10. Wang W,, Zhang X,, Qin JJ,, Voruganti S,, Nag SA,, et al. (Year: 2012) Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2. PLoS One7: e4158622911819
11. Zhang LH,, Jia YL,, Lin XX,, Zhang HQ,, Dong XW,, et al. (Year: 2013) AD-1, a novel ginsenoside derivative, shows anti-lung cancer activity via activation of p38 MAPK pathway and generation of reactive oxygen species. Biochim Biophys Acta1830: 4148–415923583729
12. Zhang X,, Xu J,, Zhang D,, Gu J,, Zhao Y, (Year: 2009) Pharmacokinetics of 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol and its active metabolite after oral and intravenous administration in rat. Xenobiotica39: 457–46419480551
13. Shi CH,, Zhang X,, Suo H,, Yin T,, Xu H,, et al. (Year: 2013) Simultaneous determination by LC-MS/MS of 25-methoxydammarane-3β,12β,20-triol epimers and active metabolites in rat plasma after intravenous administration. Xenobiotica43: 868–87423631760
14. Zhang X,, Zhang D,, Xu J,, Gu J,, Zhao Y, (Year: 2007) Determination of 25-OH-PPD in rat plasma by high-performance liquid chromatography–mass spectrometry and in rat pharmacokinetic studies. J.Chrom. B858: 65–70
15. Hao M,, Zhao Y,, Chen P,, Huang H,, Liu H,, et al. (Year: 2008) Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS One16: e269718628990
16. Li Liang,, Chen X,, Zhou J,, Zhong D, (Year: 2012) In Vitro Studies on the Oxidative Metabolism of 20 (S)-Ginsenoside Rh2 in Human, Monkey, Dog, Rat, and Mouse Liver Microsomes and Human Liver S9. Drug Metab Dispos10: 2041–205322829543

Figures

[Figure ID: pone-0094962-g001]
doi: 10.1371/journal.pone.0094962.g001.
Figure 1  Chemical structure of 25 (R)-OCH3-PPD.

[Figure ID: pone-0094962-g002]
doi: 10.1371/journal.pone.0094962.g002.
Figure 2  Full-scan mass spectrum (A) and MS2 spectrum (B) of 25 (R)-OCH3-PPD.

[Figure ID: pone-0094962-g003]
doi: 10.1371/journal.pone.0094962.g003.
Figure 3  Full-scan mass spectrum (A) and MS2 spectrum (B) of 25(R)-OH-PPD.

[Figure ID: pone-0094962-g004]
doi: 10.1371/journal.pone.0094962.g004.
Figure 4  The extracted ion chromatograms of 25(R)-OCH3-PPD and its metabolites in HLM with NADPH-regenerating system.

[Figure ID: pone-0094962-g005]
doi: 10.1371/journal.pone.0094962.g005.
Figure 5  Proposed metabolic pathways of 25 (R)-OCH3-PPD in mice, rat, dog, monkey and human microsomes.

[Figure ID: pone-0094962-g006]
doi: 10.1371/journal.pone.0094962.g006.
Figure 6  Metabolite formation of 25 (R)-OCH3-PPD incubated with NADPH-regenerating system in mice, rat, dog, monkey and human microsomes for 60 min at 37°C.

Data are presented as mean ± SD (n = 2).



[Figure ID: pone-0094962-g007]
doi: 10.1371/journal.pone.0094962.g007.
Figure 7  Effects of chemical inhibitors on the formations of metabolites after 25 (R)-OCH3-PPD (10 µM) was incubated with HLM (0.25 mg/ml).

Data are reported as mean ± SD (n = 3). *P<0.05 and **P<0.01 indicate a significant difference from the control.



[Figure ID: pone-0094962-g008]
doi: 10.1371/journal.pone.0094962.g008.
Figure 8  Metabolite M1–M7 formation of 25 (R)-OCH3-PPD (3 and 10 µM) incubated with recombinant human CYP3A4 (20 pmol/ml) with NADPH regenerating system for 30 min at 37°C.

Each data represents the mean ± SD (n = 3).



Tables
[TableWrap ID: pone-0094962-t001] doi: 10.1371/journal.pone.0094962.t001.
Table 1  The retention time, MS/MS fragment ions, 25 (R)-OCH3-PPD and its metabolites under the present LC-MS/MS conditions.
Metabolite Description TR (min) [M+H]+ Formula Product Ions of [M+H]+
M0 20.7 493 C31H56O4 475,457,443,425,407
M1 –CH2 19.1 479 C30H54O4 461,443,425,407
M2 –CH2+O–2H 11.0 493 C30H52O5 475,457,439,421,403
M3 –CH2+O 10.5 495 C30H54O5 477, 459,441,423,405
M4 +O–2H 15.5 507 C31H54O5 489,471,457,439,421,403
M5 –CH2+2O–2H 10.1 509 C30H52O6 491,473,455,437
M6 +O 14.8 509 C31H56O5 491,473,459,441,423,405
M7 +2O–2H 14.1 523 C31H54O6 505,487,473,455,437

[TableWrap ID: pone-0094962-t002] doi: 10.1371/journal.pone.0094962.t002.
Table 2  Kinetics parameters of formation of M1–M7 from 25 (R)-OCH3-PPD in human liver microsome.
Parameters M1 M2 M3 M4 M5 M6 M7
Km (µM) 26.4 1.23 19.8 19.0 1.58 24.5 4.92
Vmax(pM/min/mg) 42.1 11.5 23.2 165 11.4 113 73.2
Vmax/Kmµl/(min/mg) 1.59 9.35 1.17 8.68 7.21 4.61 14.9


Article Categories:
  • Research Article
Article Categories:
  • Biology and Life Sciences
    • Biochemistry
      • Enzymology
        • Enzyme Kinetics
        • Enzymes
      • Proteomics
        • Spectrometric Identification of Proteins
      • Metabolism
    • Organisms
      • Animals
        • Vertebrates
          • Mammals
            • Rodents
              • Rats
Article Categories:
  • Medicine and Health Sciences
    • Gastroenterology and Hepatology
Article Categories:
  • Physical Sciences
    • Chemistry
      • Analytical Chemistry
      • Medicinal Chemistry
Article Categories:
  • Research and Analysis Methods
    • Chromatographic Techniques
      • Liquid Chromatography
    • Model Organisms
      • Animal Models
        • Mouse Models


Previous Document:  L-arginine Supplementation Protects Exercise Performance and Structural Integrity of Muscle Fibers a...
Next Document:  Dll4-notch signalling blockade synergizes combined ultrasound-stimulated microbubble and radiation t...